Teva Pharmaceutical Industries Limited (TLV:TEVA)
Market Cap | 57.72B |
Revenue (ttm) | 60.26B |
Net Income (ttm) | -5.97B |
Shares Out | n/a |
EPS (ttm) | -5.28 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 835,598 |
Average Volume | 1,270,245 |
Open | 5,003.00 |
Previous Close | 5,059.00 |
Day's Range | 5,003.00 - 5,035.00 |
52-Week Range | 4,807.00 - 8,431.00 |
Beta | 0.72 |
RSI | 28.81 |
Earnings Date | May 7, 2025 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
Financial Performance
In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.
Financial numbers in USD Financial StatementsNews
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.

Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturin...
Teva, Samsung Bioepis launch biosimilar against AstraZeneca’s Soliris
Teva filing for label expansion of migraine therapy Ajovy undergoes FDA review

Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
PARSIPPANY, N.J. and TEL AVIV, April 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the U.S. Foo...
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
More than 92% of schizophrenia patients taking TEV-‘749 in the SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication1 New data from UZEDY® (...

New Data Strengthens Teva's Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
PARSIPPANY, N.J. and TEL AVIV, Israel, March 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the prese...
Teva Releases Q1 2025 Aide Memoire
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the "Investors" page on its...

Teva Releases Q1 2025 Aide Memoire
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the “Investors” page on its...

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2025 financial re...

Teva Pharmaceutical Indus Unusual Options Activity
Financial giants have made a conspicuous bearish move on Teva Pharmaceutical Indus. Our analysis of options history for Teva Pharmaceutical Indus (NYSE: TEVA) revealed 8 unusual trades. Delving into ...
Teva Pharmaceutical Industries Ltd at Barclays Global Healthcare Conference Transcript
Teva Pharmaceutical Industries Ltd at Barclays Global Healthcare Conference Transcript
Teva Pharmaceutical Industries Ltd to Discuss New Data Presented for Duvakitug (Anti-TL1A) ...
Teva Pharmaceutical Industries Ltd to Discuss New Data Presented for Duvakitug (Anti-TL1A) Phase 2b after ECCO Conference Call Transcript
Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference Transcript
Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference Transcript
Teva Pharmaceutical Stock Scores RS Rating Upgrade
Teva Pharmaceutical ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Drugmakers agree to participate in second round of price negotiations
All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals , whose medicines are part of the second round of price talks have agreed to participate in the negotiation process, a federal h...
Teva Pharmaceutical Industries Limited (TEVA) Leerink's 2025 Global Healthcare Conference (Transcript)
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Leerink's 2025 Global Healthcare Conference March 12, 2025 8:40 AM ETCompany ParticipantsRichard Francis...

This Is What Whales Are Betting On Teva Pharmaceutical Indus
Financial giants have made a conspicuous bullish move on Teva Pharmaceutical Indus. Our analysis of options history for Teva Pharmaceutical Indus (NYSE: TEVA) revealed 8 unusual trades. Delving into ...
Teva: Branded Momentum Clashes With Generic Declines And IRA Headwinds
Deckers Outdoor Corp (DECK) Unveils Teva's Spring-Summer 2025 Collection
Deckers Outdoor Corp (DECK) Unveils Teva's Spring-Summer 2025 Collection

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March
TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcom...
Teva Pharmaceutical: A Risky Bet With Potential Upside

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals
The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical mental health services across 10 states The $2 million in new funding is part...